.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Teva
Colorcon
Cerilliant
Merck
Cantor Fitzgerald
Healthtrust
Harvard Business School
Daiichi Sankyo

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,808,737

« Back to Dashboard

Which drugs does patent 8,808,737 protect, and when does it expire?


Patent 8,808,737 protects OPANA ER and is included in one NDA. There have been three Paragraph IV challenges on Opana ER.

Summary for Patent: 8,808,737

Title:Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
Inventor(s): Ahdieh; Harry (Lincoln University, PA)
Assignee: Endo Pharmaceuticals Inc. (Malvern, PA)
Application Number:12/716,973
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-001Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-002Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-003Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-004Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-005Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-006Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
Endo Pharms
OPANA ER
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL201655-007Dec 9, 2011DISCNYesNo► Subscribe► Subscribe METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
UBS
Fuji
US Department of Justice
Farmers Insurance
Cipla
Queensland Health
QuintilesIMS
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot